Leerink Global Healthcare Conference 2026
Logotype for Twist Bioscience Corporation

Twist Bioscience (TWST) Leerink Global Healthcare Conference 2026 summary

Event summary combining transcript, slides, and related documents.

Logotype for Twist Bioscience Corporation

Leerink Global Healthcare Conference 2026 summary

11 Mar, 2026

Growth drivers and market positioning

  • Achieved 20% projected growth for FY2025 and 17% last quarter, outpacing sector peers through new product introductions, share gains, and account expansion.

  • Rapidly expanded total addressable market from $2B in 2020 to $7B in 2025 by launching new products and leveraging silicon chip economics.

  • Differentiation achieved via product quality, speed, cost, and customer support, with a focus on commercial excellence and e-commerce.

  • AI-driven drug discovery products have become a fast-growing segment, demonstrating agility in identifying and meeting emerging market needs.

  • Scale, automation, and software enable delivery of thousands of protein sequences in 15-20 days, supporting high-throughput drug discovery.

Financial performance and operational strategy

  • Maintained a 24% CAGR in revenue over three years, with gross margin expanding from low 30s to over 50%.

  • 75%-80% of revenue growth drops to gross margin due to low variable costs; disciplined OpEx management supports adjusted EBITDA breakeven by Q4.

  • Shifted focus from milestone/royalty contracts to fee-for-service for faster revenue recognition, especially in monospecifics.

  • Bispecifics, enabled by Invenra B-Body technology, are expected to drive future royalties and growth.

  • Automated high-throughput facilities and targeted sales force expansion support scalable growth and margin improvement.

Market trends and customer engagement

  • AI and automation are transforming protein expression and drug discovery, with new startups and top pharma adopting these approaches.

  • Strategy is to offer a comprehensive menu (in vivo, in vitro, AI, various displays) to meet diverse customer needs and break revenue barriers.

  • Achieved $111M in therapeutics drug discovery revenue, doubling the $50M barrier and growing 21%-25% last year.

  • MRD segment is highly sticky due to speed, scale, and pricing advantages; MRD Express aims to reduce delivery from five days to one.

  • E-commerce rollout and territory-focused sales teams target under-penetrated academic and institutional markets.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
All investor relations material. One API.
Learn more